DAX24.664 -1,0%Est505.973 -0,9%MSCI World4.343 -0,1%Top 10 Crypto10,12 -2,1%Nas25.806 -0,1%Bitcoin67.833 -0,5%Euro1,1728 ±-0,0%Öl101,3 -2,0%Gold4.721 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Infineon 623100 SAP 716460 Lufthansa 823212 AMD (Advanced Micro Devices) 863186 Siemens Energy ENER6Y Allianz 840400 NEL ASA A0B733 Deutsche Telekom 555750 Amazon 906866 Novo Nordisk A3EU6F Intel 855681 Commerzbank CBK100 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX verliert 25.000-Punkte-Marke letztlich aus dem Blick -- Wall Street letztlich in Rot -- Rheinmetall gewinnt mehr -- Peloton, Infineon, Vonovia, Siemens Healthineers, Arm, IonQ, Microsoft im Fokus
Top News
Erneuerbare Energie-Aktien im Fokus: Rückenwind durch geopolitische Spannungen im Iran-Konflikt - diese 3 Aktien profitieren Erneuerbare Energie-Aktien im Fokus: Rückenwind durch geopolitische Spannungen im Iran-Konflikt - diese 3 Aktien profitieren
Morgan Stanley führt Kryptohandel ein und unterbietet Konkurrenten beim Preis Morgan Stanley führt Kryptohandel ein und unterbietet Konkurrenten beim Preis
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Relmada Therapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
6,30 EUR -0,35 EUR -5,26 %
BMN
7,42 USD -0,44 USD -5,60 %
BTT
finanzen.net zero
Relmada Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.702,71 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PSZF

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75955J4022

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolRLMD

Relmada Therapeutics Aktien News

DatumMeistgelesen
PR NewswireRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
PR NewswireRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
PR NewswireRelmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Wer­bungRelmada Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
PR NewswireRelmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
PR NewswireRelmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
PR NewswireRelmada Therapeutics Provides Corporate Update
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023
PR NewswireRelmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
PR NewswireRelmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
PR NewswireRelmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress
PR NewswireRelmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
PR NewswireRelmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
PR NewswireRelmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023
PR NewswireRLMD NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Relmada Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - RLMD
PR NewswireRelmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
PR NewswireROSEN, A LEADING LAW FIRM, Encourages Relmada Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - RLMD
PR NewswireRelmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRelmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
PR NewswireRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws
PR NewswireRelmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Relmada Therapeutics, Inc. - RLMD
PR NewswireRLMD NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Relmada Therapeutics, Inc.
PR NewswireRelmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023
PR NewswireRLMD ALERT: The Law Offices of Vincent Wong Investigate Relmada Therapeutics, Inc. for Potential Violations of Securities Laws

Relmada Therapeutics News

Relmada Therapeutics News: auf dieser Seite finden Sie alle Relmada Therapeutics News und Nachrichten zur Relmada Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Relmada Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Relmada Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.